Lakewood-Amedex flags Nu-3 antimicrobial data at IDWeek 2026

Lakewood-Amedex Biotherapeutics presented new Nu-3 data at IDWeek 2026 in Washington, D.C., highlighting rapid broad-spectrum activity and a low resistance signal. The findings matter because Nu-3 is in Phase 2a testing for mildly infected diabetic foot ulcers, with topline results expected in early 2027.

Why it matters: - Nu-3 is being developed for mildly infected diabetic foot ulcers, a setting where resistant bacteria can complicate treatment. - The new data support Lakewood-Amedex's case that Nu-3 could offer a topically delivered option against difficult-to-treat infections. - The findings also address antimicrobial resistance, one of the main challenges in infectious-disease drug development.

What happened: - Lakewood-Amedex Biotherapeutics announced a presentation on Nu-3 at IDWeek 2026 in Washington, D.C. - The poster, titled “Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers,” was scheduled for the Novel Agents session on Oct. 22, 2026, from 12:15 p.m. to 1:30 p.m. ET in Poster Hall B-C. - The company said the poster highlighted Nu-3's in-vitro activity against resistant pathogens and its low resistance potential.

The details: - Nu-3 showed broad-spectrum bactericidal activity against Gram-positive, Gram-negative and multidrug-resistant bacteria. - Tested pathogens were eradicated within minutes. - Nu-3 also showed activity against biofilm organisms. - Serial-passage testing showed only a slight increase in minimum inhibitory concentration, or MIC, against Staphylococcus aureus and Escherichia coli. - Ciprofloxacin showed a 600-fold to 2,000-fold increase in MIC in the same comparison. - The company said the findings are relevant to infected diabetic foot ulcers, where about half of ulcers become infected. - The company said an estimated 15% to 25% of diabetic foot ulcers involve resistant organisms, primarily methicillin-resistant Staphylococcus aureus, or MRSA. - Nu-3 is in an ongoing Phase 2a clinical trial in patients with mildly infected diabetic foot ulcers. - Topline data from that trial are expected in the first quarter of 2027. - Kelvin Cooper, Ph.D., Lakewood-Amedex CEO and senior vice president of research and development, said the data reinforce Nu-3's potential role against antimicrobial resistance and support its development as a differentiated therapy for iDFUs.

Between the lines: - The resistance findings are a key part of the story because durability matters as much as potency in antibiotics and related antimicrobials. - The comparison with ciprofloxacin gives Lakewood-Amedex a benchmark that makes Nu-3's resistance profile easier to understand. - The IDWeek presentation is also a visibility moment for a clinical-stage biotech that is still waiting on human efficacy readouts.

What's next: - Lakewood-Amedex will continue the Phase 2a trial of Nu-3 in mildly infected diabetic foot ulcers. - The company expects topline data in the first quarter of 2027. - Those results will help determine whether Nu-3 advances further as a topical treatment candidate. - Lakewood-Amedex also points readers to more information about the company and its B2i Digital profile.